News Updates
Current Location：Home > News Updates
News Updates > Kangda Aibo has added 3000 square meters of rabbit polyclonal antibody immunization service facilities
In 2015, Aoshima Kangda Aibo complied with market demand and established the "Rabbit Polyclonal Antibody Immunization Service Platform". With the technological and scale advantages of Kangda Group in the global rabbit industry, as well as its years of deep cultivation in the experimental animal industry, Kangda Biology has grown into a leading domestic rabbit polyclonal antibody immunization service provider.
Providing high standard services cannot be separated from high standard infrastructure, and Kangda Biotech has always spared no effort in increasing infrastructure construction. As of 2018, the "Rabbit Polyclonal Antibody Immunization Service Platform" has invested over 10 million yuan, jointly built 10000 square meters of immunization service facilities, 13000 experimental rabbit cages for immunization, and a service capacity of over 30000 rabbits per year. It provides high-quality immunization services to over 100 domestic and foreign enterprises and institutions. With the continuous expansion of market demand, Kangda Biotechnology continues to increase investment in infrastructure. In January 2019, the "Rabbit Polyclonal Antibody Immunization Service Platform" completed a new high standard immunization facility of 3000 square meters, added 3000 experimental rabbit cages for immunization, and the immunization service capacity can increase by 10000 per year.
Providing high standard services cannot be separated from high standard infrastructure, and Kangda Biotech has always spared no effort in increasing infrastructure construction. As of 2018, the "Rabbit Polyclonal Antibody Immunization Service Platform" has invested over 10 million yuan, jointly built 10000 square meters of immunization service facilities, 13000 experimental rabbit cages for immunization, and a service capacity of over 30000 rabbits per year. It provides high-quality immunization services to over 100 domestic and foreign enterprises and institutions. With the continuous expansion of market demand, Kangda Biotechnology continues to increase investment in infrastructure. In January 2019, the "Rabbit Polyclonal Antibody Immunization Service Platform" completed a new high standard immunization facility of 3000 square meters, added 3000 experimental rabbit cages for immunization, and the immunization service capacity can increase by 10000 per year.
Image above: External view of newly completed standardized immunization facilities
Image above: Internal diagram of the newly completed standardized immunization facility
Immunization is nothing small, only for those who have a heart. As long as any career is diligently polished, it will ultimately achieve impressive results. Kangda Biotechnology will continue to deepen its advantages in the four major factors of "high-quality experimental animals", "standardized production facilities", "scientific breeding technology", and "experienced technical personnel", continuously improving service quality and capabilities, and contributing its own modest efforts to the Chinese biotechnology industry.
